508
Participants
Start Date
February 14, 2013
Primary Completion Date
May 1, 2014
Study Completion Date
May 1, 2014
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
Steenokkerzeel
Deurne
Ham
Wetteren
Moorsel
Berlin
Elkridge
Shelby
Mt. Pleasant
Greenville
Atlanta
Jacksonville
Hallandale
Hollywood
Jupiter
Tampa
Foley
Nashville
New Tazewell
Magdeburg
Lexington
Columbus
Bochum
Cincinnati
Cincinnati
Cincinnati
Valparaiso
Kenosha
Rapid City
Frankfurt am Main
St Louis
Newton
Wichita
New Orleans
Carrollton
Dallas
Beaumont
Bryan
San Antonio
Salt Lake City
Salt Lake City
Los Angeles
Spring Valley
Carmichael
Milford
Coral Gables
Auburn
Brockton
Burnaby
Langley
Vancouver
Brampton
Burlington
Etobicoke
London
Newmarket
Sarnia
Stayner
Toronto
Toronto
Woodstock
Pointe-Claire
Ste-Foy
Görlitz
Leipzig
Dresden
Gdynia
Katowice
Warsaw
Wroclaw
Reading
Chesterfield
Blackpool
Bath
Bury Saint Edmonds
Coventry
Birmingham
Cardiff
Chorley
Glasgow
Liverpool
Manchester
Lead Sponsor
Bayer
INDUSTRY